Association of IL2-330 Gene Polymorphism with Lung Cancer

Öz

Cytokines are secreted or membrane-bound proteins that act as mediators of intercellular signaling to regulate homeostasis of the immune system. They are produced by cells of innate and adaptive immunity in response to microbes and tumor antigens. Although there are several studies showing that IL2-330 gene polymorphism is associated with many types of cancer, as far as we know, there is a few study investigating the association between lung cancer and IL2-330 gene polymorphism. In this study, the role of IL2-330 gene polymorphism in the pathogenesis of lung cancer was investigated. 96 patients who were diagnosed with lung cancer and 96 age and sex matched healthy subjects participated in the study. Genomic DNA was isolated using the blood DNA isolation kit and the IL2-330 gene polymorphism was determined by polymerase chain reaction-confronting two pairs primer method. When analyzed for the lung cancer group and the healthy group according to IL2-330 gene polymorphism, genotype and allele frequencies were found to be similar in both groups (p>0,05). As a result; there was no statistically significant difference between the groups. Considering the ethnic diversity of lung cancer, the study needs verified in other populations.

Anahtar Kelimeler

• Cytokines
• Interleukine 2
• IL2
• Lung cancer
• Polymorphism

IL2-330 Gen Polimorfizminin Akciğer Kanseri ile İlişkisinin Araştırılması

Öz

Sitokinler, bağışıklık sisteminin homeostazını düzenlemek için hücreler arası sinyalleşmenin aracıları olarak görev yapan, salgılanan veya zara bağlı proteinlerdir. Mikroplara ve tümör antijenlerine yanıt olarak doğuştan gelen bağışıklığa sahip hücreler tarafından üretilirler. IL2-330 gen polimorfizminin birçok kanser türü ile ilişkili olduğunu gösteren birkaç çalışma olmasına rağmen, bildiğimiz kadarıyla akciğer kanseri ile IL2-330 gen polimorfizmi arasındaki ilişkiyi araştıran az sayıda çalışma vardır. Bu çalışmada IL2-330 gen polimorfizminin akciğer kanseri patogenezindeki rolü araştırılmıştır. Çalışmaya akciğer kanseri tanısı almış 96 hasta ile yaş ve cinsiyet bakımından uyumlu 96 sağlıklı, gönüllü birey katıldı. Genomik DNA izolasyon kiti kullanılarak izole edildi ve IL2 -330 gen polimorfizmi polimeraz zincir reaksiyonu ile iki çift primer yöntemiyle karşılaştırılarak belirlendi. Akciğer kanserinde IL2-330 gen polimorfizmine göre hasta grubu ve sağlıklı grup incelendiğinde genotip ve allel frekanslarının her iki grupta benzer olduğu görüldü (p>0,05). Sonuç olarak gruplar arasında istatistiksel olarak anlamlı bir fark yoktu. Akciğer kanserinin etnik çeşitliliği göz önüne alındığında, çalışmanın diğer popülasyonlarda da doğrulanması gerekmektedir.

Anahtar Kelimeler

• Sitokin
• Interlökin 2
• IL2
• Akciğer kanseri
• Polimorfizm

Kaynakça

1. Medler Terry R, Cotechini Tiziana, Coussens Lisa M. Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance. Trends in cancer. 2015;1:66-75.
2. Bindon C, Czerniecki M, Ruell P, Edwards A, McCarthy WH, Harris R, Hersey P. Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects. British journal of cancer. 198347(1);123-133.
3. Seder RA, Paul WE. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annual review of immunology, 1994; 2(1):635-673.
4. Torres-Mejía G, Angeles-Llerenas A, Ortega-Olvera C, Lazcano-Ponce E, Ziv E, Pulido-Rodríguez J, et al. Moderate-intensity physical activity ameliorates the breast cancer risk in diabetic women. Diabetes Care,.2012;35(12):2500-2502.
5. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nature Reviews Immunology. 2004:4(9):665-674.
6. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature, 2011;480;480-489.
7. Winchester DA, Till C, Goodman PJ, Tangen CM, Santella RM, Johnson‐Pais TL, et al. Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial. The Prostate. 2015;75(13),:1403-1418.
8. John S, Turner D, Donn R, Sinnott P, Worthington J, Ollier WER, et al. Two novel biallelic polymorphisms in the IL‐2 gene. European Journal of Immunogenetics. 1998;25(6);419-420.

9. Matesanz F, Delgado C, Fresno M, Alcina A. Allelic selection of human IL‐2 gene. European journal of immunology. 2010;30(12):3516-3521.
10. Hoffmann SC, Stanley EM, Cox ED, Craighead N, DiMercurio BS, Koziol DE, et al. Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-cd3/cd28-stimulated peripheral blood lymphocytes1. Transplantation. 2001;72(8):1444-1450.
11. Noronha IL, Niemir Z, Stein H, Waldherr R. Cytokines and growth factors in renal disease. Nephrology Dialysis Transplantation. 1995;10(6):775-786.
12. Smith AJ, Humphries SE. Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine & growth factor reviews. 2009;20(1):43-59.
13. Melchiades JL, Zabaglia LM, Sallas ML, et al. Polymorphisms and haplotypes of the interleukin 2 gene are associated with an increased risk of gastric cancer. The possible involvement of Helicobacter pylori. Cytokine. 2017;96:203-207.
14. Amirzargar AA, Bagheri M, Ghavamzadeh A, Alimoghadam K, Khosravi F, Rezaei N, Nikbin B, et al. Cytokine gene polymorphism in Iranian patients with chronic myelogenous leukaemia. International journal of immunogenetics. 2005;32(3):167-171.
15. Togawa S, Joh T, Itoh M, Katsuda N, Ito H, Matsuo K, et al. Interleukin-2 gene polymorphisms associated with increased risk of gastric atrophy from Helicobacter pylori infection. Helicobacter. 2005;10(3):172-178.
16. Shin WG, Jang JS, Kim HS, Kim SJ, Kim KH, Jang MK, et al. Polymorphisms of interleukin-1 and interleukin-2 genes in patients with gastric cancer in Korea. J Gastroenterol Hepatol. 2008;23(10):1567-1573.
17. Wu J, Lu Y, Ding YB, Ke Q, Hu ZB, Yan ZG, et al. Promoter polymorphisms of IL2, IL4, and risk of gastric cancer in a high-risk Chinese population. Mol Carcinog. 2009;48(7):626-632.
18. Forones NM, Mandowsky SV, Lourenço LG. Serum levels of interleukin-2 and tumor necrosis factor-alpha correlate to tumor progression in gastric cancer. Hepatogastroenterology. 2001;48(40):1199-1201.
19. Orditura M, Romano C, De Vita F, Galizia G, Lieto E, Infusino S, et al. Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival. Cancer Immunol Immunother. 2000;49(10):530-536.
20. Klein B, Levin I, Kfir B, Mishaeli M, Shapira J, Klein T. The significance of soluble interleukin-2, soluble interleukin-2 receptors, soluble ICAM-1 and beta 2-microglobulin in breast cancer patients. Tumour Biol. 1995;16(5):290-296.
21. Zhao H, Wang R. IL2 -330T/G polymorphism and cancer risk: a meta-analysis. Onco Targets Ther. 2015;8:1753-1760.
22. Song N, Han S, Lee KM, Choi JY, Park SK, Jeon S, et al. Genetic variants in interleukin-2 and risk of lymphoma among children in Korea. Asian Pac J Cancer Prev. 2012;13(2):621-623.
23. Wei YS, Lan Y, Zhang L, Wang JC. Association of the interleukin-2 polymorphisms with interleukin-2 serum levels and risk of nasopharyngeal carcinoma. DNA Cell Biol. 2010;29(7):363-368.